华熙生物(688363) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was RMB 1,360,531,915, representing a year-on-year increase of 4.24%[4] - The net profit attributable to shareholders was RMB 243,367,321.40, reflecting a year-on-year growth of 21.39%[4] - The net profit after deducting non-recurring gains and losses was RMB 231,475,776.61, which increased by 53.30% compared to the same period last year[4] - Basic and diluted earnings per share were both RMB 0.51, marking a 21.43% increase year-on-year[5] - Net profit for Q1 2024 was CNY 243,387,652.32, compared to CNY 200,972,272.94 in Q1 2023, reflecting an increase of approximately 21.0%[20] - Basic earnings per share for Q1 2024 were CNY 0.51, up from CNY 0.42 in Q1 2023, representing a growth of approximately 21.4%[21] Cash Flow - The net cash flow from operating activities was RMB 34,851,268.21, with a significant increase attributed to reduced expenses and employee bonuses[8] - In Q1 2024, the net cash flow from operating activities was 34,851,268.21, a significant improvement from -198,334,371.86 in Q1 2023[23] - Total cash inflow from operating activities was 1,380,453,113.82, compared to 1,524,539,434.51 in the same period last year, reflecting a decrease of approximately 9.4%[22] - Cash outflow from operating activities totaled 1,345,601,845.61, down from 1,722,873,806.37 in Q1 2023, indicating a reduction of about 21.9%[23] - The ending balance of cash and cash equivalents was 571,232,634.73, down from 1,106,405,377.17 at the end of Q1 2023, representing a decrease of approximately 48.3%[24] Assets and Liabilities - Total assets at the end of the reporting period were RMB 8,315,390,858.15, a decrease of 1.83% from the end of the previous year[5] - The company's total assets as of March 31, 2024, amounted to RMB 8,315,390,858.15, compared to RMB 8,470,008,293.83 as of December 31, 2023[16] - The company reported a total liability of CNY 1,188,057,942.06, down from CNY 1,486,581,550.49, indicating a decrease of approximately 20.0%[18] - The total equity attributable to shareholders increased to CNY 7,087,986,444.98 from CNY 6,944,100,603.15, a growth of about 2.1%[18] Research and Development - Research and development expenses totaled RMB 95,741,342.10, accounting for 7.04% of operating revenue, which is an increase of 0.67 percentage points from the previous year[5] - Research and development expenses rose to CNY 95,741,342.10 from CNY 83,153,130.85, marking an increase of about 15.5%[19] Shareholder Information - The top ten shareholders held a total of 58.86% of the shares, with the largest shareholder owning 283,500,000 shares[9] - As of April 26, 2024, the company has repurchased a total of 3,040,219 shares, accounting for 0.6312% of the total share capital of 481,678,242 shares, with a total expenditure of RMB 203,975,735.27[14] Government Support and Investments - The company received government subsidies amounting to RMB 11,028,362.09, which are closely related to its normal business operations[6] - The company received 7,139,138.96 in investment income, an increase from 4,737,573.13 in Q1 2023, reflecting a growth of about 50.7%[23] - The company has established strategic partnerships for investment in medical ventures, indicating a focus on expanding its healthcare investment portfolio[12] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[20]